Results 101 to 110 of about 32,646 (215)

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

AMPK‐mediated prevention of vascular dysfunction with metformin: Experimental and population‐based evidence

British Journal of Pharmacology, Volume 183, Issue 17, Page 5389-5406, September 2026.
Angiotensin II induces vascular inflammation, senescence, extracellular matrix (ECM) degradation and endothelial dysfunction, thus impairing SK+/IK+ channel function and reducing endothelial‐dependent hyperpolarisation (EDH). Metformin activates AMPK, increasing SK+/IK+ channel function and restoring vasorelaxation.
Soroush Mohammadi Jouabadi, Annika A. Jüttner, Annique Claringbould, Rene de Vries, Ingrid M. Garrelds, Usha Musterd‐Bhaggoe, Bruno H. Stricker, Maryam Kavousi, A. H. Jan Danser, Fariba Ahmadizar, Anton J. M. Roks   +10 more
wiley   +1 more source

Harnessing MDM2‐Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma

Advanced Science, Volume 13, Issue 45, 13 August 2026.
MDM2 dependency in pediatric sarcomas is driven by a novel p53‐independent oncogenic cistrome alongside canonical p53 pathway suppression. This study introduces MDM2‐recruiting transcriptional and epigenetic machinery degraders (MDM2‐TEMADs) as a novel precision oncology modality.
Jiawei Zhou, Xian Guan, Nan Li, Ying Zhang, Long Xie, Xingze Huang, Zhipeng Zhu, Zhuolin Ren, Xiaoyan Yu, Hanjun Guo, Yuanfang Wu, Lin Ma, Suya Zheng, Jingyao Zhang, Jiyang Liu, Victor Kuanmin Lee, Wenhao Chen, H. Phillip Koeffler, Jinhu Wang, Xin Han, Ye Chen, Liang Xu   +21 more
wiley   +1 more source

The Host Cell Factor Phosphatase‐2A Subunit PR130 Restricts Replication of Herpes Simplex Virus Type‐1

Advanced Science, Volume 13, Issue 44, 7 August 2026.
Molecular, genetic, virological, and biochemical analysis in combination with global proteome and phosphoproteome profiling and functional assays were applied to study the role of PR130 in the context of HSV‐1 replication. The observations reveal that host‐intrinsic mechanisms regulate HSV‐1 replication and highlight PR130 as a susceptibility factor of
Johannes Jungwirth, Christoph F. Jacob, Alexandra Nguyen, Mandy Beyer, Andreas O. Mieland, Mario Dejung, Jia‐Xuan Chen, Walburgis Brenner, Christina Ehrhardt, Andreas Henke, Oliver H. Krämer   +10 more
wiley   +1 more source

Respiratory Virus-Induced PARP1 Alters DC Metabolism and Antiviral Immunity Inducing Pulmonary Immunopathology

Viruses
Previous studies from our laboratory and others have established the dendritic cell (DC) as a key target of RSV that drives infection-induced pathology. Analysis of RSV-induced transcriptomic changes in RSV-infected DC revealed metabolic gene signatures ...
Mohamed M. Mire, Srikanth Elesela, Susan Morris, Gabriel Corfas, Andrew Rasky, Nicholas W. Lukacs   +5 more
doaj   +1 more source

A Catalytic Osmium Redox Couple Collapses Cancer Redox Balance

Advanced Science, Volume 13, Issue 43, 3 August 2026.
A stable Os(III)/Os(IV) redox couple is developed to disrupt the tumor cell redox balance by concurrently catalyzing ROS generation and GSH depletion. Osmium‐treated cells exhibit multiple cell death pathways, including apoptosis, ferroptosis, and immunogenic cell death.
Wan‐Qiong Huang, Tao Huang, Yiming Hao, Gui‐Feng Huang, Yi‐Lang Yan, Xin Fang, Ying Chen, Xiao‐Long Wei, Wai‐Lun Man, Wen‐Xiu Ni   +9 more
wiley   +1 more source

Update on PARP1 inhibitors in ovarian cancer

Annals of Oncology, 2011
The clinical development of PARP inhibitors for the treatment of tumors deficient in BRCA1 or BRCA2 is based on the concept of synthetic lethality. From the initial proof of concept study with the PARP1 inhibitor olaparib (AZD2281) in BRCA mutation carriers, in which 28% of ovarian cancer patients achieved an objective response, the target population ...
openaire   +3 more sources

PARP1 condensates differentially partition DNA repair proteins and enhance DNA ligation

EMBO Reports
Poly(ADP-ribose) polymerase 1 (PARP1) is one of the first responders to DNA damage and plays crucial roles in recruiting DNA repair proteins through its activity – poly(ADP-ribosyl)ation (PARylation). The enrichment of DNA repair proteins at sites of DNA
Christopher Chin Sang, Gaelen Moore, Maria Tereshchenko, Hongshan Zhang, Michael L Nosella, Morgan Dasovich, T Reid Alderson, Anthony K L Leung, Ilya J Finkelstein, Julie D Forman-Kay, Hyun O Lee   +10 more
doaj   +1 more source

Current Advances of Molecular Biomarkers and Liquid Biopsies Techniques in Ovarian Cancer

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Ovarian cancer (OC) remains a lethal gynecological malignancy with challenges in early diagnosis, treatment monitoring, and overcoming drug resistance. Liquid biopsy, a noninvasive approach analyzing tumor‐derived components in bodily fluids, has emerged as a promising tool in OC management.
Jingxia Zhang, Weiyan Shan, Jie Yu, Huan Shi, Qiaoping Xu, Hongkai Shang   +5 more
wiley   +1 more source

Resveratrol Inhibits Nucleosome Binding and Catalytic Activity of PARP1

Biomolecules
The natural polyphenol resveratrol is a biologically active compound that interacts with DNA and affects the activity of some nuclear enzymes. Its effect on the interaction between nucleosomes and poly(ADP-ribose) polymerase-1 (PARP1) and on the ...
Daria O. Koshkina, Natalya V. Maluchenko, Anna N. Korovina, Angelina A. Lobanova, Alexey V. Feofanov, Vasily M. Studitsky   +5 more
doaj   +1 more source